News - VHIO

12 November 2024

Next-generation SERD camizestrant significantly reduces risk of disease progression in patients with advanced ER+ HER2- breast cancer

• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…

07 Sep: VHIO tests a new combination of drugs for HER2-positive breast cancer without the adverse effects of conventional chemotherapy

This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody

1 … 77 78